Menu Search
Equities

Revenio Group Oyj

REG1V:HEX

Revenio Group Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)29.20
  • Today's Change0.12 / 0.41%
  • Shares traded14.25k
  • 1 Year change+29.89%
  • Beta1.3967
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform3
Hold2
Sell0
Strong Sell1

Share price forecast in EUR

The 6 analysts offering 12 month price targets for Revenio Group Oyj have a median target of 32.00, with a high estimate of 35.00 and a low estimate of 26.00. The median estimate represents a 9.59% increase from the last price of 29.20.
High19.9%35.00
Med9.6%32.00
Low-11.0%26.00

Dividends in EUR

In 2023, Revenio Group Oyj reported a dividend of 0.38 EUR, which represents a 5.56% increase over last year. The 6 analysts covering the company expect dividends of 0.39 EUR for the upcoming fiscal year, an increase of 1.84%.
Div growth (TTM)5.56%
More ▼

Earnings history & estimates in EUR

On Oct 31, 2024, Revenio Group Oyj reported 3rd quarter 2024 earnings of 0.16 per share.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+6.95%
Revenio Group Oyj reported annual 2023 earnings of 0.719 per share on Feb 15, 2024.
Average growth rate+20.72%
More ▼

Revenue history & estimates in EUR

Revenio Group Oyj had 3rd quarter 2024 revenues of 23.90m. This missed the 24.90m consensus estimate of the 4 analysts following the company. This was 3.02% above the prior year's 3rd quarter results.
Average growth rate+3.77%
Revenio Group Oyj had revenues for the full year 2023 of 96.60m. This was 0.41% below the prior year's results.
Average growth rate+18.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.